Drug Discovery Today ( IF 7.4 ) Pub Date : 2017-07-18 , DOI: 10.1016/j.drudis.2017.07.006 Luong T.H. Nguyen , Aristo Muktabar , Jinkai Tang , Vinayak P. Dravid , C. Shad Thaxton , Subbu Venkatraman , Kee Woei Ng
Atherosclerosis is one of the leading causes of morbidity and mortality worldwide. Nanotechnology has provided the possibility of designing nanoparticles that can translocate through tissues and home in to atherosclerotic plaques to achieve desired diagnostic, therapeutic, theranostic or ‘theralivery’ outcomes. Although nanomedicine approaches have demonstrated exciting possibilities, clinical reality is still distant and challenges are aplenty, such as specificity of targeting and nanotoxicity. Nevertheless, developments in formulations, delivery strategies and experimental models over the coming years will generate new knowledge to define the true potential of this field. This review discusses the most recent developments, current challenges and future possibilities.
中文翻译:
用于检测,治疗和预防动脉粥样硬化的工程纳米颗粒:我们有多近?
动脉粥样硬化是全世界发病率和死亡率的主要原因之一。纳米技术提供了设计纳米颗粒的可能性,该纳米颗粒可以通过组织移位并进入动脉粥样硬化斑块,以实现所需的诊断,治疗,治疗或“治疗”效果。尽管纳米医学方法已显示出令人兴奋的可能性,但临床现实仍然遥遥无期,挑战众多,例如靶向的特异性和纳米毒性。然而,在未来几年中,制剂,给药策略和实验模型的发展将产生新的知识,以定义该领域的真正潜力。这篇评论讨论了最新的发展,当前的挑战和未来的可能性。